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Deep Brain Stimulation is currently being investigated as an experimental treatment
for patients suffering from treatment-refractory AN, with an increasing number of case
reports and small-scale trials published. Although still at an exploratory and experimental
stage, initial results have been promising. Despite the risks associated with an invasive
neurosurgical procedure and the long-term implantation of a foreign body, DBS has a
number of advantageous features for patients with SE-AN. Stimulation can be fine-tuned
to the specific needs of the particular patient, is relatively reversible, and the technique
also allows for the crucial issue of investigating and comparing the effects of different
neural targets. However, at a time when DBS is emerging as a promising investigational
treatment modality for AN, lesioning procedures in psychiatry are having a renaissance.
Of concern it has been argued that the two kinds of interventions should instead be
understood as rivaling, yet “mutually enriching paradigms” despite the fact that lesioning
the brain is irreversible and there is no evidence base for an effective target in AN. We
argue that lesioning procedures in AN are unethical at this stage of knowledge and
seriously problematic for this patient group, for whom self-control is particularly central to
wellbeing. They pose a greater risk of major harms that cannot justify ethical equipoise,
despite the apparent superiority in reduced short term surgical harms and lower cost.
Keywords: deep brain stimulation, neurosurgery for psychiatric disease, medical ethics, anorexia nervosa,
autonomy
Anorexia Nervosa (AN) has the highest mortality rate of all psychiatric disorders (1), and existing
treatment modalities have limited effect (2). In this context, there has been burgeoning interest
in applying Deep Brain Stimulation (DBS) to the treatment of patients suffering from Severe and
Enduring Anorexia Nervosa (SE-AN) (3). Whilst there is some disagreement about the precise
diagnostic thresholds for when AN develops into SE-AN (4), here we shall adopt a widely accepted
definition of SE-AN according to which a patient suffers from SE-AN if they have suffered from
AN for over 7 years, and they have exhausted intensive inpatient and outpatient treatment options
(5). SE-AN is thus distinct from other manifestations of AN that have not yet met duration and/or
treatment-resistant criteria.
Concurrently, ablative neurosurgery has also been posited as a rivaling treatment for psychiatric
disorders. A recent Chinese study by Liu et al. (6) investigated Bilateral Anterior Capsulotomy
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in the treatment of patients of AN of lesser (>3 years) duration.
Notably, participants had not received all alternative treatment
modalities recommended by evidence-based guidelines provided
by organizations such as the National Institute for Health and
Care Excellence [e.g., (7)], as these were not available. For
example, participants in the study had only undergone 3 months
of psychotherapy, whilst NICE recommends that individual
eating-disorder-focused Cognitive Behavioral Therapy (CBT-
ED) should typically consist of up to 40 sessions over 40 weeks
(7). Accordingly, participants in Liu et al.’s study do not qualify
as suffering from SE-AN according to the definition that we adopt
here.
In Liu et al.’s study, BMI increased, but as there was no
measure of eating disorder psychopathology, it is unclear if this
was a consequence of on-going disordered eating. The authors
respectfully acknowledged that their patients are different from
those deemed treatment refractory in other countries, as there
was little available eating disorder expertise in China-and that
had this been available these patients might have recovered
without surgery. Despite this, and of concern to us, a published
follow-up comment on this study suggested that ethical research
into DBS and stereotactic ablation for AN can and should
proceed in parallel.
Here, we argue in favor of prioritizing research into DBS
as a neurosurgical treatment modality for SE-AN, and explain
why at this point in our scientific understanding DBS should be
prioritized over ablative interventions, and reserved for patients
with SE-AN as we have defined it here.
All neurosurgical interventions for SE-AN must currently be
considered experimental. Therefore, great care must be taken to
protect patients from harm (8). Of course, patients receiving DBS
for any indication are unavoidably put at risk of some harm, since
they must first undergo an invasive neurosurgical procedure.
They must also maintain an implanted foreign device for a long
period of time. However, since there are few published reports of
DBS in the treatment of SE-AN, it is difficult to fully assess its
safety and efficacy in this context. Nonetheless, the feasibility of
this approach has been demonstrated (3).
Whilst the risk posed by DBS for movement disorders is
generally deemed to be acceptably low, the potential risk of
surgical complications and non-compliance may be exacerbated
in the context of DBS treatment SE-AN, due to patients’ severe
chronic malnutrition (8). Moreover, the limited evidence base
on efficacy and on the optimal neural target for stimulation
in SE-AN makes it difficult to assess whether DBS will benefit
a particular patient. Nonetheless, whilst further research is
necessary, emerging evidence of DBS for SE-AN is promising
(3), and our published neuroethical guidelines argue that the
potential benefits of DBS can outweigh its risks and costs for some
carefully selected patients (8).
Despite its attendant risks, DBS has a number of advantages
as a neurosurgical intervention. First, in so far as its effects
are stimulation-dependent, DBS is reversible; and on ceasing
stimulation, the physical components of the DBS system
can be explanted. Despite emerging evidence suggesting that
DBS can lead to some non-stimulation dependent long term
effects (9, 10), overall long-term evidence of other potential
non-stimulation-dependent effects of DBS is lacking (11).
Moreover the evidence from DBS for movement disorders
suggests that significant therapeutic effects and side-effects of
the procedure are stimulation-dependent. This has the important
implication that patients who do not view the therapeutic effect
and/or the side-effects of treatment positively can stop the effects
of treatment. It is true that this will come at the cost of either a
further neurosurgical procedure, or the long-term maintenance
of a latent device in the body. However, we believe that the
benefits of reversibility can outweigh these costs, due to the
implications that it has for the control that patients may exert
over their treatment. This is particularly important in the context
of SE-AN, as we explain below.
As compared to lesioning not only is DBS relatively reversible,
it is also patient-specific, since voltages can be fine-tuned to the
specific sensitivities of the patient. Furthermore, DBS also allows
for the option of exploring the effects of different neural targets.
This latter feature is particularly important, given that no one
neural target has proven efficacy in SE-AN. Treatment teams can
modulate neural activity in a particular brain region posited to
be central to a patient’s pathophysiology and track neural and
symptomatic effects in order to optimize and individualize the
treatment. Double blinded on-off phases can also be incorporated
into protocols to explore the potential influence of placebo
effects (12).
However, at a time when DBS is emerging as a promising
investigational treatment modality for AN, lesioning procedures
in psychiatry more generally are also having a renaissance.
Although ablative neurosurgery in psychiatry has a notorious
history, it has been argued that technological developments and
robust consent procedures have allowed for safer and more
effective interventions (13).
While there is some precedent for ablative surgery in other
psychiatric disorders (13), like DBS, there is currently very little
evidence supporting the efficacy of ablative neurosurgery for
SE-AN (14). Furthermore, there are no published systematic
comparisons between DBS and ablative neurosurgery for any
psychiatric indication (15). We thus currently lack the data
to make an informed comparison between the effectiveness
of DBS and ablative neurosurgery for SE-AN, and at this
stage of experimental investigation an ablative procedure risks
permanent harm.
Nonetheless, notwithstanding any potential differences in
effectiveness, it has been suggested that ablative neurosurgery
may have some advantages over DBS as a general treatment
method for some psychiatric patients, particularly those
exhibiting co-morbid substance abuse or personality disorders,
even though it is irreversible, non-adjustable, and arguably poses
a greater risk of neurological side-effects than DBS (15, 16).
The main reason offered in favor of this view is that ablative
neurosurgery does not require the long-term maintenance
of an implanted device; as such, it poses lower risk of post-
operative infection, and is likely to be less expensive than
long-term DBS treatment (15). It might also be suggested that
DBS for psychiatric disorders typically requires the use of high
voltage stimulation, which might lead to short battery life
and the need for major recovery surgery every several years.
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However, this additional concern can be circumvented by
the use of rechargeable devices, which will last over 10 years
even at high voltages needed, as employed in our recent trial
protocol (12).
Given the considerations outlined above, some commentators
have argued that DBS and ablative neurosurgery should be
understood as rivaling, yet “mutually enriching paradigms” in
psychiatry (16). On this “rival paradigms” approach, ablative
neurosurgery is understood to be based on a “quick fix”
paradigm, whilst DBS is understood to be based on a paradigm
of “adjustability” (16). Neither paradigm is understood to be
absolutely superior, but rather each paradigm is associated with
a different set of costs and benefits for particular patients (16).
On the contrary though, we believe that DBS and ablative
neurosurgery are not equal rivals in the context of SE-AN.
We argue that DBS should be prioritized as an investigational
treatment modality for SE-AN, and that lesioning procedures
are not ethically justifiable at this stage of knowledge, given the
greater risk of major harms they pose, in addition to the lack of
evidence regarding their efficacy.
In our view, and that of our patients, lesioning is particularly
problematic for patients for whom control is central, and it
potentially poses a greater risk of major harms. This claim may
seem surprising, since it might be argued that ablative procedures
would be practically or medically preferable to DBS for SE-AN
patients in particular, due to their pronounced infection risk,
and lower likelihood of compliance with long-term follow up.
However, the justification for this claim is that reversibility and
adjustability are particularly valuable in the context of SE-AN,
because of the particular vulnerabilities of these patients (8).
SE-AN is often an ego-syntonic disorder, and patients can
experience considerable ambivalence about recovery (8). With a
highly limited evidence base for effective treatments, many with
SE-AN have few options remaining to them and feel hopeless.
At the same time, the sense of control and identity which SE-
AN can provide can mean that while desperate for recovery,
patients may at the same time feel terrified of losing control of
the recovery process, and uncertain of their identity should they
begin to recover. Psychological control thus plays a central role in
the etiology and maintenance of SE-AN.
Accordingly, the adjustability and reversibility of DBS
takes on a particularly significant value in SE-AN, since
these features allow the individual to retain an important
sphere of control, even while making a momentous decision
to undergo neurosurgery. Most obviously, the patient can
choose to cease stimulation, and even have the device
explanted. Significantly, the patient who chooses to continue
stimulation still continues to make active choices in collaboration
with their treatment teams about her treatment, which
reduces the likelihood of experiencing a loss of control.
This adjustability also enables treatment teams to make
greater allowances for the potential ambivalence of the
patient toward treatment and to maintain engagement in a
collaborative process of working toward recovery with DBS.
In contrast, irreversible ablative neurosurgery, particularly give
the lack of proven efficacy, does not allow for this sphere of
control.
Indeed, patients in our current trial of DBS have echoed this
line of argument. The following is a quotation from a patient
interviewed about positive effects of DBS treatment for SE-
AN at 12-month follow-up. The patient offered the following
(unprompted) reflections on hearing about brain lesioning
procedures for SE-AN:
. . .And I thought to myself, I wouldn’t do that.. .because then it’s
very permanent and irreversible. . . although you wouldn’thave to
have the device (and for amoment I thought, well, it would be nice
not to have a snake running down my front,) but then I thought,
no, I wouldn’t want that. It seems to take the choice out of it. . . .
Furthermore, in a recently published case study of ablative
neurosurgery performed on an ego-dystonic SE-AN patient, the
authors note that when the patient was asked at a 3-month
follow-up whether “she would have had the surgery knowing
what she knows now,” she answered negatively (17). This is
despite the fact that the patient had consented to the procedure,
and her condition had improved according to many objective
measures. Although the patient changed to answer the question
positively at 1-year follow up, this example shows the potential
difficulties when deploying an irreversible procedure in patients
who may experience ambivalence about their condition, and the
dangers of offering irreversible surgical treatment to this patient
group.
In summary, surgical ablation is a process where the
alteration is “done to” the passive patient; whereas DBS is a
dynamic process in which the patient is actively involved in
making on-going decisions with the surgical and psychiatric
team. We believe that there is a legitimate concern regarding
the ethical basis, acceptability, and the potential impact of
ablative neurosurgery on SE-AN patients, and DBS should be
favored despite its higher cost because of its adjustability and
reversibility.
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